Deal drives stock move
Aligos Therapeutics Inc. reported a 21% gain in its shares during after-hours trading Monday after receiving a $25 million upfront payment tied to an exclusive licensing agreement with Xiamen Amoytop Biotech Co., Ltd.
Scope of the license
The agreement grants Amoytop exclusive rights to develop and commercialize pevifoscorvir sodium for the treatment of chronic hepatitis B virus infection within Greater China. Aligos will retain all development and commercialization rights for the asset in the United States, Europe, South Korea, Japan, and other markets outside Amoytop’s licensed territory.
Financial terms and potential revenue
- Aligos received a $25 million upfront payment as part of the transaction.
- The company is eligible to receive up to $420 million in clinical, regulatory, and sales milestones under the agreement.
- Amoytop will also pay tiered, high single-digit royalties on net sales in the licensed territories.
Regulatory designation in China
Pevifoscorvir sodium has been granted Breakthrough Therapy Designation by the Center for Drug Evaluation of China’s National Medical Products Administration. That designation is reserved for new drugs treating serious diseases where preliminary evidence suggests efficacy, and it makes the drug eligible for priority review of a New Drug Application in China.
Collaboration governance and next steps
Aligos said a joint steering committee with Amoytop has been formed to supervise the collaboration. The companies are also coordinating plans to advance Aligos’ antisense oligonucleotide candidate, ALG-170675, into clinical trials in China during the third quarter of 2026.
Company focus
Aligos Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for liver and viral diseases.
Note: This article reports the facts of the agreement, regulatory designation, and stated timelines as released by the company.